Hospitals Face Profit Squeeze As Policy Risks Grow: Analyst
BofA warns hospitals face profit and volume pressure from policy cuts, favors post-acute care, upgrades Brookdale, and sees select names better positioned to weather challenges.
Vistagen’s Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
Republicans Seek Documents, Schedule Hearing Related To FDA’s Response To Baby-Formula Shortage
House Republicans are reportedly speeding up their scrutiny of the FDA and the White House's handling of the baby formula shortage last year.
Despite Failed Phase 3 Study, FDA Staff Says Biogen’s ALS Drug May Have Clinical Benefit
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc’s (NASDAQ:BIIB) ALS…
The Inevitable End – SVB Financial Officially Files For Bankruptcy In New York
SVB Financial Group (NASDAQ:SIVB) has filed a voluntary petition for a court-supervised reorganization under Chapter 11 in the United States Bankruptcy…
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Dermavant Sciences, a Roivant Sciences Ltd. (NASDAQ:ROIV) company, announced results from ADORING 2 Phase 3 study evaluating VTAMA (tapinarof) cream, 1% in…
ThermoGenesis Rolls Out Manufacturing Suites For Use In Early-Stage Cell, Gene Therapy, Shares Soar
ThermoGenesis Holdings Inc (NASDAQ:THMO) is rolling out a new facility in the Sacramento metro area, containing 12 class-7, ReadyStart…
Silicon Valley Bank Creditors Purchased Bonds At Distressed Levels Anticipating Potential Bankruptcy Sale
Silicon Valley Bank's parent, SVB Financial Group's (NASDAQ: SIVB) creditors, have formed a group in the case of a potential bankruptcy filing.
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera,…
Why Jounce Therapeutics Stock Is Moving Higher Today?
The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…